The strong revenue growth and pipeline catalysts (KB803, KB801, KB407 data in 2H 2026) support a bullish outlook, but monitor pricing negotiations in Europe and upcoming clinical data readouts.
KRYS drugs
KRYS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $286.95entry
- T+1 · 7mo ago −0.83%α −1.62% · $284.57
- T+5 · 6mo ago +9.04%α +6.10% · $312.88
- T+20 · 6mo ago +3.89%α −1.76% · $298.10
- T+60 · 4mo ago +26.60%α +24.74% · $363.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up 52.5% YoY. Pipeline advancements include complete enrollment for KB803 and on-track readouts for KB801 and KB407 in 2026.
Key Financial Metrics
Key Facts
- Q1 2026 VYJUVEK net product revenue of $116.4M, +32% YoY
- Diluted EPS of $1.83 vs $1.20 in Q1 2025
- Gross margin of 95% for Q1 2026
- Registrational studies for KB803 (DEB corneal abrasions) and KB801 (neurotrophic keratitis) on track for data readouts in 2026
- FDA granted platform technology designation for KB407 (CF) and KB111 (HHD)
- Cash and investments of $1.0 billion at quarter end
- FY2026 non-GAAP combined R&D and SG&A expense guidance of $175M-$195M
Financial Impact
Q1 revenue of $116.4M, net income of $55.9M, EPS of $1.83 diluted; significant beat vs prior year
Risk Factors
- Pricing and reimbursement negotiations in Germany, France, Italy, and Spain may delay international revenue growth
- Clinical trial risks for pipeline candidates (KB801, KB407, KB803)
- Competition from other gene therapies for DEB and other indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286550 |
Track record
18 reports on KRYS
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.97% at T+20 after the Aug 3, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
- Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
- Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers